- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02659345
Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients
January 25, 2017 updated by: Case Comprehensive Cancer Center
Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients Undergoing Chemotherapy Treatment
Participants in this research study are asked to tell about their experience with art therapy.
Participants in this research study are currently receiving chemotherapy treatment for cancer.
The purpose of this study is to learn how art therapy affects mood, anxiety, pain, and emotions of individuals with cancer who are undergoing chemotherapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this single-center single-arm non-controlled descriptive study, we aim to describe the effects of a single art therapy session on a cancer patient's mood, pain, anxiety level.
Primary Objectives
- To assess the effect of art therapy on the cancer patient's mood
- To assess the effect of art therapy on the cancer patient's anxiety
- To assess the effect of art therapy on the cancer patient's pain
Secondary Objectives
- To explore differences in response to art therapy by ethnic group, race, age, sex, caregiver support, cancer diagnosis, reason for visit, and marital status
- To explore differences in response to art therapy by primary concern expressed by patients during art therapy sessions
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Weston, Florida, United States, 33331
- Maroone Cancer Center - Cleveland Clinic Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects are able to give informed consent
- Any cancer diagnosis
- Actively undergoing any chemotherapy treatment at Maroone Cancer Center
- Patients who have never utilized art therapy at Maroone Cancer Center
- Speaks, reads, and writes in English
- Able and willing to participate in an art therapy session at Maroone Cancer Center
Exclusion Criteria:
- Patients without cancer diagnosis
- Patients not actively undergoing chemotherapy at Maroone Cancer Center
- Individuals unable to complete art therapy activities independently due to physical and/or mental impairment
- Under 18 years of age (minors)
- Patients who have dementia or a legal guardian
- Unable to speak, read, and write in English
- Patients who have previously utilized art therapy at Maroone Cancer Center
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Art Therapy
The art therapy intervention will be executed by an art therapist at the Cancer Center.
The same art therapy practices that are utilized in daily practice will be employed in this study.
The intervention will include assessment of patient's needs and goals in addition to utilization of various art modalities.
Sessions will conclude with processing of the art and supportive counseling as appropriate.
Pilot testing of the intervention has been performed informally at Maroone Cancer Center with positive feedback provided by patients and their support systems to the physicians, nurses, and art therapist.
Change in pain, emotional distress, depression, adn anxiety will be measured by the emotions thermometer.
|
The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study.
For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level).
The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level.
This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes.
The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials.
The session will conclude with processing of the art and supportive counseling.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect of art therapy on the cancer patient's mood
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The primary endpoint of the trial is to access the effect of an art therapy session on the patients' mood, anxiety level, and pain.
To accomplish this, patients will complete four visual analog scales (VAS) prior to and after the session.
The primary end points are the pre-and post session changes in the VAS.
|
Change from baseline to after intervention, about 50 minutes
|
The effect of art therapy on the cancer patient's anxiety
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The primary endpoint of the trial is to access the effect of an art therapy session on the patients' mood, anxiety level, and pain.
To accomplish this, patients will complete four visual analog scales (VAS) prior to and after the session.
The primary end points are the pre-and post session changes in the VAS.
|
Change from baseline to after intervention, about 50 minutes
|
The effect of art therapy on the cancer patient's pain
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The primary endpoint of the trial is to access the effect of an art therapy session on the patients' mood, anxiety level, and pain.
To accomplish this, patients will complete four visual analog scales (VAS) prior to and after the session.
The primary end points are the pre-and post session changes in the VAS.
|
Change from baseline to after intervention, about 50 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and ethnic group of patients
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and race of patients
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and age of patients
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and sex of patients
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and caregiver support of patients
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and cancer diagnosis of patients
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and reason for visit of patients
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and marital status of patients
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and primary concern expressed by patients during art therapy session
Time Frame: Change from baseline to after intervention, about 50 minutes
|
The secondary goal is to assess, in an exploratory manner, associations between VAS scores (baseline and changes) and patient characteristics as well as patients' expressed primary concerns.
Data will be analyzed using methods such as 2-sample and paired t-tests, ANOVA, and Pearson correlations.
|
Change from baseline to after intervention, about 50 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Steven Roshon, MD, Cleveland Clinic Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
January 25, 2016
Study Completion (Actual)
January 25, 2017
Study Registration Dates
First Submitted
January 14, 2016
First Submitted That Met QC Criteria
January 15, 2016
First Posted (Estimate)
January 20, 2016
Study Record Updates
Last Update Posted (Estimate)
January 26, 2017
Last Update Submitted That Met QC Criteria
January 25, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CASE5Z15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Emotions Thermometer
-
University Hospital, CaenInstitut National de la Santé Et de la Recherche Médicale, France; La Région... and other collaboratorsCompleted
-
Geon CorporationActive, not recruitingHealthy | FebrileTaiwan
-
NHS Greater Clyde and GlasgowThales GroupActive, not recruiting
-
Tyto Care LtdUnknownBody Temperature MeasurementIsrael
-
Radboud University Medical CenterCompleted
-
Memorial University of NewfoundlandHealth Care Foundation, NL, Canada; Association of Registered Nurses of Newfoundland... and other collaboratorsCompleted
-
University of ArkansasCompleted
-
Brighton and Sussex University Hospitals NHS TrustCompleted
-
Oslo University HospitalCompleted